203 lines
6.6 KiB
YAML
203 lines
6.6 KiB
YAML
abstract: 'An individual''s experience of COPD is determined by many factors in
|
|
|
|
addition to the pathological features of chronic bronchitis and
|
|
|
|
emphysema and the symptoms that derive directly from them.
|
|
|
|
Multimorbidity is the norm rather than the exception, so most people
|
|
|
|
with COPD are living with a range of other medical problems which can
|
|
|
|
decrease overall quality of life. COPD is caused by the inhalation of
|
|
|
|
noxious particles or gases, in particular tobacco smoke, but also by
|
|
|
|
early life disadvantage impairing lung development and by occupations
|
|
|
|
where inhaled exposures are common (e.g. industrial, farming and
|
|
|
|
cleaning work). Wealthy people are therefore relatively protected from
|
|
|
|
developing COPD and people who do develop the condition may have reduced
|
|
|
|
resources to cope.
|
|
|
|
COPD is also no longer a condition that predominantly affects men. The
|
|
|
|
prevalence of COPD among women has equalled that of men since 2008 in
|
|
|
|
many high-income countries, due to increased exposure to tobacco, and in
|
|
|
|
low-income countries due to biomass fuels. COPD is one of the leading
|
|
|
|
causes of death in women in the USA, and death rates attributed to COPD
|
|
|
|
in women in some countries are predicted to overtake those of men in the
|
|
|
|
next decade. Many factors contribute to this phenomenon, but in addition
|
|
|
|
to socioeconomic and occupational factors, there is increasing evidence
|
|
|
|
of a higher susceptibility of females to smoking and pollutants. Quality
|
|
|
|
of life is also more significantly impaired in women. Although most
|
|
|
|
medications (bronchodilators and inhaled corticosteroids) used to treat
|
|
|
|
COPD demonstrate similar trends for exacerbation prevention and lung
|
|
|
|
function improvement in men and women, this is an understudied area and
|
|
|
|
clinical trials frequently have a preponderance of males. A better
|
|
|
|
understanding of gender-based predictors of efficacy of all therapeutic
|
|
|
|
interventions is crucial for comprehensive patient care. There is an
|
|
|
|
urgent need to recognize the increasing burden of COPD in women and to
|
|
|
|
facilitate global improvements in disease prevention and management in
|
|
|
|
this specific population.
|
|
|
|
Many individuals with COPD follow a trajectory of both lung function
|
|
|
|
decline and also multimorbidity. Unfavourable lung function trajectories
|
|
|
|
throughout life have implications for later development of other chronic
|
|
|
|
diseases. An enhanced understanding of the temporal associations
|
|
|
|
underlying the development of coexisting diseases is a crucial first
|
|
|
|
step in unravelling potential common disease pathways. Lessons can be
|
|
|
|
learned from exploring disease trajectories of other NCD as well as
|
|
|
|
multimorbidity development. Further research will be essential to
|
|
|
|
explain how early life risk factors commonly influence trajectories of
|
|
|
|
COPD and other diseases, how different diseases develop in relation to
|
|
|
|
each other in a temporal way and how this ultimately leads to different
|
|
|
|
multimorbidity patterns in COPD.
|
|
|
|
This review integrates new knowledge and ideas pertaining to three broad
|
|
|
|
themes (i) the overall burden of disease in COPD, (ii) an unappreciated
|
|
|
|
high burden in women and (iii) the contrast of COPD trajectories and
|
|
|
|
different multimorbidity patterns with trajectories of other NCD. The
|
|
|
|
underlying pathology of COPD is largely irreversible, but many factors
|
|
|
|
noted in the review are potentially amenable to intervention. Health and
|
|
|
|
social care systems need to ensure that effective treatment is
|
|
|
|
accessible to all people with the condition. Preventive strategies and
|
|
|
|
treatments that alter the course of disease are crucial, particularly
|
|
|
|
for patients with COPD as one of many problems.'
|
|
affiliation: 'Zysman, M (Corresponding Author), CHU Bordeaux, Serv Malad Resp, Ave
|
|
Magellan, F-33604 Pessac, France.
|
|
|
|
Hopkinson, NS (Corresponding Author), Imperial Coll, Natl Heart \& Lung Inst, Royal
|
|
Brompton Hosp Campus,Fulham Rd, London SW3 6HP, England.
|
|
|
|
Vanfleteren, LEGW (Corresponding Author), Univ Gothenburg, Sahlgrenska Univ Hosp,
|
|
COPD Ctr, Dept Resp Med \& Allergol,Inst Med, Vita Straket 12, SE-41345 Gothenburg,
|
|
Sweden.
|
|
|
|
Buttery, Sara C.; Hopkinson, Nicholas S., Imperial Coll London, Natl Heart \& Lung
|
|
Inst, London, England.
|
|
|
|
Zysman, Maeva, Univ Bordeaux, Ctr Rech Cardiothorac Bordeaux, Pessac, France.
|
|
|
|
Zysman, Maeva, CHU Bordeaux, Serv Malad Resp, Ave Magellan, F-33604 Pessac, France.
|
|
|
|
Vikjord, Sigrid A. A., Nord Trondelag Hosp Trust, Levanger Hosp, Dept Med \& Rehabil,
|
|
Levanger, Norway.
|
|
|
|
Vikjord, Sigrid A. A., Norwegian Univ Sci \& Technol NTNU, Fac Med \& Hlth Sci,
|
|
HUNT Res Ctr, Dept Publ Hlth \& Nursing, Levanger, Norway.
|
|
|
|
Jenkins, Christine, George Inst Global Hlth, Resp Grp, Sydney, NSW, Australia.
|
|
|
|
Vanfleteren, Lowie E. G. W., Sahlgrens Univ Hosp, COPD Ctr, Dept Resp Med \& Allergol,
|
|
Gothenburg, Sweden.
|
|
|
|
Vanfleteren, Lowie E. G. W., Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Internal
|
|
Med \& Clin Nutr, Gothenburg, Sweden.'
|
|
author: Buttery, Sara C. and Zysman, Maeva and Vikjord, Sigrid A. A. and Hopkinson,
|
|
Nicholas S. and Jenkins, Christine and Vanfleteren, Lowie E. G. W.
|
|
author-email: 'maeva.zysman@chu-bordeaux.fr
|
|
|
|
n.hopkinson@ic.ac.uk
|
|
|
|
lowie.vanfleteren@gu.se'
|
|
author_list:
|
|
- family: Buttery
|
|
given: Sara C.
|
|
- family: Zysman
|
|
given: Maeva
|
|
- family: Vikjord
|
|
given: Sigrid A. A.
|
|
- family: Hopkinson
|
|
given: Nicholas S.
|
|
- family: Jenkins
|
|
given: Christine
|
|
- family: Vanfleteren
|
|
given: Lowie E. G. W.
|
|
da: '2023-09-28'
|
|
doi: 10.1111/resp.14032
|
|
earlyaccessdate: MAR 2021
|
|
eissn: 1440-1843
|
|
files: []
|
|
issn: 1323-7799
|
|
journal: RESPIROLOGY
|
|
keywords: 'frailty; inequality; patient perspective; patient\&\#8208; reported
|
|
|
|
outcome measure; symptoms'
|
|
keywords-plus: 'OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; BLOOD-PRESSURE
|
|
|
|
TRAJECTORIES; ALL-CAUSE MORTALITY; BODY-MASS INDEX; LUNG-FUNCTION;
|
|
|
|
PHYSICAL-ACTIVITY; CHRONIC-BRONCHITIS; PRIMARY-CARE; DEVELOPMENTAL
|
|
|
|
ORIGINS'
|
|
language: English
|
|
month: MAY
|
|
number: '5'
|
|
number-of-cited-references: '255'
|
|
orcid-numbers: 'Jenkins, Christine/0000-0003-2717-5647
|
|
|
|
ZYSMAN, Maeva/0000-0003-1459-2409
|
|
|
|
Buttery, Sara/0000-0001-9410-414X
|
|
|
|
Vanfleteren, Lowie/0000-0002-4387-4096'
|
|
pages: 419-441
|
|
papis_id: 2c387d7a48355931411eaf1fc01f7d92
|
|
ref: Buttery2021contemporaryperspect
|
|
researcherid-numbers: 'ZYSMAN, Maéva/ACP-5812-2022
|
|
|
|
OMOSIGHO, BLESSING/ISS-7818-2023
|
|
|
|
'
|
|
tags:
|
|
- review
|
|
times-cited: '14'
|
|
title: 'Contemporary perspectives in COPD: Patient burden, the role of gender and
|
|
trajectories of multimorbidity'
|
|
type: article
|
|
unique-id: WOS:000626772700001
|
|
usage-count-last-180-days: '4'
|
|
usage-count-since-2013: '17'
|
|
volume: '26'
|
|
web-of-science-categories: Respiratory System
|
|
year: '2021'
|